Nationwide survey of severe respiratory syncytial virus infection in children who do not meet indications for palivizumab in Japan-Reference-Cited by-同舟云学术

Nationwide survey of severe respiratory syncytial virus infection in children who do not meet indications for palivizumab in Japan

Published:2011 Issue:2 Volume:17 Page:254-263
ISSN:1341-321X
Container-title:Journal of Infection and Chemotherapy
language:en
Short-container-title:Journal of Infection and Chemotherapy

Author:

Mori Masaaki,Kawashima Hisashi,Nakamura Hidefumi,Nakagawa Masao,Kusuda Satoshi,Saji Tsutomu,Tsutsumi Hiroyuki,Yokota Shumpei,Itoh Susumu

Publisher

Elsevier BV

Subject

Infectious Diseases,Pharmacology (medical),Microbiology (medical)

Link

http://www.springerlink.com/index/pdf/10.1007/s10156-010-0121-1

Reference26 articles.

1. Infectious Disease Surveillance Center. Infectious Agents Surveillance Report 29(10), October 2008. Available at: http://idsc.nih.go.jp/iasr/29/344/tpc344.html. Accessed 6 November 2009.

2. Respiratory syncytial virus;Hall,2004

3. Respiratory syncytial virus infection;Tsutsumi;Kansenshogaku Zasshi,2005

4. Red Book: 2006 report of the Committee on Infectious Diseases,2006

5. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants;Pediatrics,1998

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Factors Associated With Hospitalization, Length of Stay, and Hospital Expenditures for Respiratory Syncytial Virus Infection in Japanese Infants and Children According to Palivizumab-indicated Underlying Conditions: The LIFE Study;Pediatric Infectious Disease Journal;2024-09-11

2. Impact of respiratory syncytial virus on older children: Exploring the potential for preventive strategies beyond the age of 2 years;Vaccine;2024-08

3. Evolving Epidemiology of Pediatric Respiratory Syncytial Virus (RSV) Cases Around COVID-19 Pandemic: Impact and Clinical Insights, Retrospective Cohort Study;Journal of Epidemiology and Global Health;2024-04-04

4. Safety, efficacy and pharmacokinetics of palivizumab in off-label neonates, infants, and young children at risk for serious respiratory syncytial virus infection: a multicenter phase II clinical trial;The Lancet Regional Health - Western Pacific;2023-10

5. Current methods of preventing infectious disease and managing febrile neutropenia in childhood cancer patients: a nationwide survey in Japan;International Journal of Clinical Oncology;2022-12-31